Adial Pharmaceuticals (ADIL) Q3 2025 earnings summary

Executive summary

• Achieved key milestones for AD04, including successful End of Phase 2 FDA meeting, Phase 3 trial design aligned with FDA guidance, and validation of biomarker-positive and negative groups.

• No products approved or significant revenue generated; operations funded by equity, warrant inducements, and offerings.

• Net loss of $6.0 million for the nine months ended September 30, 2025, with an accumulated deficit of $88 million.

• Cash and cash equivalents of $4.6 million at quarter-end, sufficient to fund operations into Q2 2026.

• Strategic partnership discussions ongoing, expected to accelerate as milestones are reached.

Financial highlights

• Research and development expenses decreased 20% year-over-year to $2.0 million for the nine months ended September 30, 2025; Q3 R&D expenses decreased by $511 thousand (50%) year-over-year.

• General and administrative expenses increased 2% year-over-year to $3.9 million for the nine months ended September 30, 2025; Q3 G&A expenses increased by $63 thousand (5%) year-over-year.

• Net loss for the nine months ended September 30, 2025 was $6.0 million, compared to $11.1 million in the prior year period; Q3 2025 net loss was $1.8 million, improved from $2.2 million in Q3 2024.

• Inducement expense of $4.5 million in 2024 was a one-time, noncash item; no similar expense in 2025.

• Cash used in operations was $5.2 million for the nine months ended September 30, 2025.

Outlook and guidance

• Cash on hand expected to fund operations into the second quarter of 2026; additional capital required for continued development.

• Plans to begin Phase 3 study of AD04 in first half of 2026, contingent on funding and regulatory progress.

• Anticipates strategic partnerships to accelerate as further milestones are achieved.

• Expects commercial companion diagnostic test to be available for physician or at-home use following FDA approval.

• No committed sources of funding; management actively pursuing financing and strategic alternatives.